ECSP24013075A - Proteina de cápside de aav5 modificada aislada vp1 - Google Patents

Proteina de cápside de aav5 modificada aislada vp1

Info

Publication number
ECSP24013075A
ECSP24013075A ECSENADI202413075A ECDI202413075A ECSP24013075A EC SP24013075 A ECSP24013075 A EC SP24013075A EC SENADI202413075 A ECSENADI202413075 A EC SENADI202413075A EC DI202413075 A ECDI202413075 A EC DI202413075A EC SP24013075 A ECSP24013075 A EC SP24013075A
Authority
EC
Ecuador
Prior art keywords
capsid protein
increase
efficiency
raav5
aav5 capsid
Prior art date
Application number
ECSENADI202413075A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021124727A external-priority patent/RU2820088C1/ru
Application filed filed Critical
Publication of ECSP24013075A publication Critical patent/ECSP24013075A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente solicitud está relacionada con los campos de la terapia génica y la biología molecular. Más concretamente, la presente invención se refiere a una proteína VP1 de cápside modificada y aislada del virus adenoasociado de serotipo 5 (AAV5), que comprende una o más sustituciones de aminoácidos en comparación con la proteína de cápside de AAV5 de tipo salvaje, cuyas sustituciones aumentan la eficiencia de la transducción, aumentan la eficiencia de empaquetamiento de genomas virales AAV con productos basados en rAAV5, y también aumentan la eficiencia de producción (ensamblado) de un vector basado en el virus adenoasociado recombinante de serotipo 5 (rAAV5), a una cápside y a un vector basado en la mencionada VP1, así como a usos de los mismos.
ECSENADI202413075A 2021-08-20 2024-02-19 Proteina de cápside de aav5 modificada aislada vp1 ECSP24013075A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021124727A RU2820088C1 (ru) 2021-08-20 Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе

Publications (1)

Publication Number Publication Date
ECSP24013075A true ECSP24013075A (es) 2024-03-01

Family

ID=85240919

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202413075A ECSP24013075A (es) 2021-08-20 2024-02-19 Proteina de cápside de aav5 modificada aislada vp1

Country Status (11)

Country Link
EP (1) EP4389759A1 (es)
CN (1) CN117881689A (es)
AR (1) AR126840A1 (es)
AU (1) AU2022329630A1 (es)
CA (1) CA3229587A1 (es)
CO (1) CO2024001681A2 (es)
EC (1) ECSP24013075A (es)
IL (1) IL310961A (es)
MA (1) MA64619A1 (es)
TW (1) TW202315947A (es)
WO (1) WO2023022633A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP1453547B1 (en) * 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
EP3693025B1 (en) 2011-04-22 2021-10-13 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
MY172457A (en) 2012-04-18 2019-11-26 Childrens Hospital Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
CA3209883A1 (en) * 2013-07-22 2015-01-29 The Children's Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
RU2751592C2 (ru) 2019-08-22 2021-07-15 Общество С Ограниченной Ответственностью "Анабион" Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе

Also Published As

Publication number Publication date
MA64619A1 (fr) 2024-04-30
CN117881689A (zh) 2024-04-12
CO2024001681A2 (es) 2024-06-27
IL310961A (en) 2024-04-01
EP4389759A1 (en) 2024-06-26
TW202315947A (zh) 2023-04-16
AR126840A1 (es) 2023-11-22
CA3229587A1 (en) 2023-02-23
WO2023022633A1 (ru) 2023-02-23
AU2022329630A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
CL2020000728A1 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas.
CO2022001833A2 (es) Proteína vp1 modificada aislada de la cápside del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en la misma.
CL2018003196A1 (es) Cápsides variantes de virus adenoasociados y métodos de uso de estas.
PE20210915A1 (es) Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis
EA202090332A1 (ru) Улучшенная продукция капсида aav в клетках насекомых
PE20190401A1 (es) Novedosas proteinas de la capside del virus adenoasociado
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
PE20160188A1 (es) Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos
CO2021016198A2 (es) Composiciones útiles para el tratamiento de la enfermedad de pompe
BR112020003976A8 (pt) Vírus adeno-associado (aav) com domínio fosfolipase modificado
MX2022013819A (es) Capsides de virus adeno-asociado 5 modificado y usos del mismo.
CO2022017334A2 (es) Ácido nucleico codón-optimizado que codifica la proteína smn1 y su uso
CO2023009633A2 (es) Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal
CO2022016956A2 (es) Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd)
ECSP24013075A (es) Proteina de cápside de aav5 modificada aislada vp1
AR123369A1 (es) VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2
PE20121171A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
ECSP24013002A (es) Proteína vp1 de la cápsida aav9 modificada aislada
CO2024001455A2 (es) Sistema de expresión de baculovirus
UY39659A (es) Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación ix y su uso
AR123245A1 (es) Nuevas cápsulas de aav y composiciones que las contienen
CO2024001768A2 (es) Método para obtener una cápside de virus adenoasociado modificada
AR120259A1 (es) Variantes de aav3b con rendimiento mejorado de la producción y tropismo hepático